Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients
Open Access
- 1 November 2011
- journal article
- review article
- Published by Taylor & Francis Ltd in Breast Cancer: Targets and Therapy
- Vol. 3, 151-60
- https://doi.org/10.2147/bctt.s12955
Abstract
Peer reviewed article authored by (Chan VTC, Yeo W). Read article or submit your manuscript for publishing.Keywords
This publication has 54 references indexed in Scilit:
- Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trialSupportive Care in Cancer, 2010
- Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapySupportive Care in Cancer, 2009
- Chemotherapy-Induced Nausea and VomitingThe New England Journal of Medicine, 2008
- Emerging drugs for chemotherapy-induced emesisEmerging Drugs, 2006
- The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trialsEuropean Journal of Cancer, 2005
- Acute emesis: moderately emetogenic chemotherapySupportive Care in Cancer, 2004
- Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapySupportive Care in Cancer, 2004
- AprepitantDrugs, 2004
- Antiemetic prescription in Italian breast cancer patients submitted to adjuvant chemotherapySupportive Care in Cancer, 2003
- Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869Cancer, 2002